An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models

Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations. Clinical application of istradefylline for the management of other...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropharmacology 2016-11, Vol.110 (Pt A), p.48-58
Hauptverfasser:	Ko, Wai Kin D., Camus, Sandrine M., Li, Qin, Yang, Jianzhong, McGuire, Steve, Pioli, Elsa Y., Bezard, Erwan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine A2 Receptor Antagonists - administration & dosage Animals Cognition Cognition Disorders - drug therapy Cognition Disorders - physiopathology Cognition Disorders - psychology Dose-Response Relationship, Drug Drug Evaluation, Preclinical - methods Drug Therapy, Combination Dyskinesia, Drug-Induced - drug therapy Dyskinesia, Drug-Induced - physiopathology Dyskinesia, Drug-Induced - psychology Environmental Sciences Female Hypokinesia - drug therapy Hypokinesia - physiopathology Hypokinesia - psychology Istradefylline KW-6002 l-DOPA-induced dyskinesia Levodopa - administration & dosage Levodopa - toxicity Life Sciences Macaca fascicularis Motor Skills Disorders - drug therapy Motor Skills Disorders - physiopathology Motor Skills Disorders - psychology MPTP MPTP Poisoning - drug therapy MPTP Poisoning - physiopathology MPTP Poisoning - psychology Parkinson's disease Purines - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!